Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study

Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis

(2022) Maria G. Tektonidou   JOURNAL OF AUTOIMMUNITY

Effect of PCSK9 on Vascular Smooth Muscle Cell Functions: A New Player in Atherosclerosis

(2021) Qiong Xiang et al.   CURRENT MEDICINAL CHEMISTRY

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

(2021) Vittoria Cammisotto et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study

(2021) Daniele Pastori et al.   Journal of Clinical Medicine

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology

(2021) Sai Sahana Sundararaman et al.   Biomedicines

Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study

(2021) Tommaso Bucci et al.   THROMBOSIS RESEARCH

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

(2020) Nicholas A. Marston et al.   CIRCULATION

PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation

(2020) Vittoria Cammisotto et al.   Antioxidants

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial

(2020) Rafael Diaz et al.   European Journal of Preventive Cardiology

PCSK9 and LRP5 in macrophage lipid internalization and inflammation

(2020) Lina Badimon et al.   CARDIOVASCULAR RESEARCH

PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36

(2020) Zhiyong Qi et al.   CIRCULATION

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall

(2020) Yanan Guo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PCSK9 and atherosclerosis: Looking beyond LDL regulation

(2020) Rosetta Ragusa et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis

(2020) Mira Merashli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis

(2019) Daniele Pastori et al.   AUTOIMMUNITY REVIEWS

EULAR recommendations for the management of antiphospholipid syndrome in adults

(2019) Maria G Tektonidou et al.   ANNALS OF THE RHEUMATIC DISEASES

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

(2019) Massimo Radin et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort

(2019) Daniele Pastori et al.   ATHEROSCLEROSIS

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

PCSK9 as a Positive Modulator of Platelet Activation

(2018) Marina Camera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis

(2018) Savino Sciascia et al.   RHEUMATOLOGY

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   JOURNAL OF HYPERTENSION

Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation

(2017) Daniele Pastori et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice

(2017) Hui Wang et al.   Scientific Reports

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE

(2016) Karin Leander et al.   CIRCULATION

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers

(2016) Eguzkine Ochoa et al.   PLoS One

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events

(2015) Paul M. Ridker et al.   EUROPEAN HEART JOURNAL

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

(2014) R Cervera et al.   ANNALS OF THE RHEUMATIC DISEASES

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Atherosclerosis in thrombotic primary antiphospholipid syndrome

(2009) P. R. J. AMES et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

(2009) V. PENGO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS